Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Research Report 2025 Market To Reach $14.34 Billion By 2034, Driven By Innovative R&D, Strategic Collaborations, And Drug Formulation Advancements

(MENAFN- GlobeNewsWire - Nasdaq) The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by rising diabetes and obesity rates, innovative drug formulations, and supportive healthcare policies, the market is expanding. Key players include Eli Lilly, Sanofi, and Novo Nordisk. Challenges involve high costs and regulatory complexities. Opportunities lie in obesity treatment expansion and advanced drug delivery systems.

Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034" has been added to ResearchAndMarkets.com's offering.

The Europe glucagon-like peptide-1 (GLP-1) agonists market is projected to witness significant growth, fueled primarily by an increased prevalence of type 2 diabetes and obesity. Originally valued at USD 7.09 billion in 2024, the market is estimated to expand at a compound annual growth rate (CAGR) of 17.30%, expecting a valuation of USD 14.34 billion by 2034.

The competitive landscape features major pharmaceutical firms like Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and others focused on innovative R&D, strategic collaborations, and drug formulation advancements. These companies aim to enhance market presence through mergers, acquisitions, and partnerships that promote access and compliance, ensuring sustained growth in the Europe's GLP-1 agonists market.

The market's expansion is propelled by the increasing incidence of diabetes and obesity, augmented by sedentary lifestyles and poor dietary choices. GLP-1 agonists, as incretin-based therapies, are preferred for their efficacy in controlling blood sugar levels and facilitating weight loss, crucial aspects in managing diabetes and obesity. The growth trajectory is supported by rising healthcare expenditure, a burgeoning elderly demographic, advancements in drug delivery, and a robust regulatory framework favoring novel therapeutic adoption.

Key Attributes:

Report Attribute	Details
No. of Pages	300
Forecast Period	2025 - 2034
Estimated Market Value (USD) in 2025	$7.09 Billion
Forecasted Market Value (USD) by 2034	$14.34 Billion
Compound Annual Growth Rate	7.3%
Regions Covered	Europe

Market Drivers

• A surge in type 2 diabetes and obesity cases.
• Favorable government initiatives and reimbursement policies bolstering access to innovative treatments.
• Improved drug formulations like once-weekly injectables and oral options enhancing patient compliance.
• A growing trend towards combination therapies integrating GLP-1 agonists for optimized results.

Market Challenges

• High costs of GLP-1 therapies affecting widespread accessibility.
• Potential side effects that could hinder patient adherence.
• Regulatory complexities delaying new therapy commercializations.

Future Opportunities

• Expanding applications in obesity treatment beyond diabetes management.
• Innovative drug delivery system developments heightening market penetration.
• Strategic R&D investments for next-gen GLP-1 therapies with enhanced efficacy.

Europe GLP-1 Agonists Market Trends

• The shift towards long-acting GLP-1 formulations like once-weekly injections elevating patient compliance.
• The increasing use of GLP-1 agonists in obesity management, supported by regulatory endorsements.
• Clinical validation of cardiovascular benefits driving GLP-1 adoption among patients at cardiovascular risk.
• Policymaker efforts in expanding healthcare coverage improving treatment accessibility.
• The development of multi-target GLP-1 therapies promises superior management of diabetes and weight issues.
• Strategic collaborations in biosimilar production broadening market access and affordability.

Market Segmentation

• By Drugs: Key drugs include dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide.
• By Application: The applications span type 2 diabetes mellitus and obesity treatment.
• By Route of Administration: Dominated by parenteral routes, the market is gradually seeing a rise in oral solution adoption.
• By End User: Primary users are hospitals, specialty clinics, academic research sites, with home care settings gaining traction.
• By Distribution Channel: Hospital pharmacies prevail, while retail and online pharmacies steadily gain ground.
• By Region: The United Kingdom, Germany, France, and Italy emerge as principal markets, bolstered by strong infrastructure and supportive policies.

Companies Featured

• Eli Lilly and Company
• Sanofi
• Novo Nordisk A/S
• AstraZeneca plc

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• European Glucagon-like Peptide-1 (GLP-1) Agonists Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN14072025004107003653ID1109796816